Dupilumab use in asthma linked to higher lymphoma risk, especially T/NK cell types, though overall mortality was lower, new ...

Adults on dupilumab for severe chronic rhinosinusitis with nasal polyps had better outcomes than those who used omalizumab, ...

[A]lthough our findings found that there is insufficient evidence to suggest that dupilumab use is associated with joint pain, the prevalence of joint pain observed among patients treated with ...

Discover a study where results suggest a statistically significant association between dupilumab and psoriasis, although the clinical impact may be limited.

Bio-Thera Solutions and SteinCares have signed a new agreement to commercialize a proposed biosimilar of dupilumab across ...

Recent FDA decisions added new options for dermatologists involved in treating patients with psoriasis, bullous pemphigoid ...

Biologics, including medications like mepolizumab and dupilumab, are widely prescribed for patients with severe asthma and ...

The Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adult patients with bullous pemphigoid.

Etokimab (I-Mab Biopharma), which is optimized for common IL-33 gene polymorphisms, has completed patient recruitment in its ...

Learn how Dupixent helps diverse eczema patients and why inclusive clinical trials are vital for fair healthcare.

Biological drugs have been a game-changer for people with severe asthma, helping them breathe easier and live more ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...